Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PRENW | US
0
0%
Healthcare
Diagnostics & Research
30/06/2024
13/03/2026
0.02
0.02
0.02
0.02
Prenetics Global Limited an investment holding company operates as a diagnostics and genetic testing company. Its products include CircleDNA a consumer genetic testing product; and Circle HealthPod a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot an off-the-shelf at-home blood test; Circle Medical a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay Hong Kong.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
35.0%1 month
71.1%3 months
98.6%6 months
255.1%-
-
-
0.01
0.01
-
-
-
-36.70M
-
-
-
-178.56
-
4.30
-21.67
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.00
Range1M
0.01
Range3M
0.01
Rel. volume
0.92
Price X volume
787.68
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| STRRP | STRRP | Diagnostics & Research | 10.06 | 0 | 0.20% | n/a | 26.85% |
| bioAffinity Technologies Inc. Warrant | BIAFW | Diagnostics & Research | 0.3299 | 0 | 36.10% | n/a | 40.20% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | - | 12.67 | - |
| Ent. to Revenue | - | 44.00 | - |
| PE Ratio | - | 40.09 | - |
| Price to Book | - | 77.50 | - |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 98.55 | 59.59 | Riskier |
| Debt to Equity | 0.01 | -14.36 | Expensive |
| Debt to Assets | 0.01 | 0.34 | Cheaper |
| Market Cap | - | 13.71B | - |